12:00 AM
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Everolimus: Phase I/II data

Researchers at Children's Hospital Medical Center, Cincinnati, and colleagues reported data from an open-label, U.S. Phase I/II trial in 20 pediatric patients with a confirmed diagnosis of TSC and medically-refractory epilepsy showing that everolimus for 12 weeks reduced seizure frequency by >=50% from baseline, the primary endpoint, in 12 patients. Additionally, 4 patients were free of seizures and 7 patients had a >=90% reduction in seizure frequency from baseline. Everolimus...

Read the full 326 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >